meer-TAZ-a-peen 
Unlabeled Use:
Contraindicated in:
Use Cautiously in:
CV: edema, hypotension.
Derm: BULLOUS DERMATITIS, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), ERYTHEMA MULTIFORME, pruritus, rash, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS.
EENT: sinusitis.
Endo: SIADH.
F and E: ↑ thirst, hyponatremia.
GI: ↑ appetite, constipation, dry mouth, ↑ liver enzymes, abdominal pain, anorexia, nausea, vomiting.
GU: urinary frequency.
Hemat: AGRANULOCYTOSIS.
Metab: weight gain, hypercholesterolemia, hypertriglyceridemia.
MS: arthralgia, back pain, myalgia.
Neuro: drowsiness, abnormal dreams, abnormal thinking, agitation, akathisia, anxiety, apathy, confusion, dizziness, hyperkinesia, hypoesthesia, malaise, NEUROLEPTIC MALIGNANT SYNDROME, SUICIDAL THOUGHTS, twitching, weakness.
Resp: cough, dyspnea.
Misc: flu-like syndrome, SEROTONIN SYNDROME.
Drug-Drug:
Drug-Natural Products:
(Generic available)
Therapeutic Classification: antidepressants
Pharmacologic Classification: tetracyclic antidepressants
Absorption: Well absorbed but rapidly metabolized, resulting in 50% bioavailability.
Distribution: Unknown.
Protein Binding: 85%.
Metabolism/Excretion: Extensively metabolized by the liver by the CYP1A2, CYP2D6, and CYP3A isoenzymes; metabolites excreted in urine (75%) and feces (15%).
Half-life: 20–40 hr.
NDC Code*